Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | CTPS1 | P17812 | 4/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24088759 | 1.00 | CYP11B2 (0.49) | CYP11B2L3MBTL1PIM1CSNK2A1PIM3 | |
| SCHEMBL24088757 | 0.88 | CYP11B2 (0.52) | CYP11B2L3MBTL1CTPS1CYP11B1 | |
| SCHEMBL31676652 | 0.88 | CYP11B2 (0.52) | CYP11B2L3MBTL1CTPS1CYP11B1 | |
| SCHEMBL21391995 | 0.86 | CTPS1 (0.52) | CYP11B2PIM1CSNK2A1PIM3PIM2 | |
| SCHEMBL29488942 | 0.86 | CTPS1 (0.52) | CYP11B2PIM1CSNK2A1PIM3PIM2 | |
| SCHEMBL24088643 | 0.82 | L3MBTL1 (0.58) | CYP11B2L3MBTL1PIM3DGAT1 | |
| SCHEMBL21044091 | 0.81 | CYP11B2 (0.53) | CYP11B2L3MBTL1PIM1PIM3PIM2 | |
| SCHEMBL24088712 | 0.80 | CYP11B2 (0.49) | CYP11B2PIM1CSNK2A1PIM3PIM2 | |
| SCHEMBL30455804 | 0.80 | CYP11B2 (0.49) | CYP11B2PIM1CSNK2A1PIM3PIM2 | |
| SCHEMBL21392128 | 0.79 | CTPS1 (0.53) | CYP11B2PIM1PIM3PIM2CTPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319680-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20230183229-A1 | Compounds | SYGNATURE DISCOVERY LIMITED (GB) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183229-A1 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CYP11B2 10/4885L3MBTL1 3515/4885PIM1 1455/4885 |
| US-12319680-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | CYP11B2 10/4885L3MBTL1 3515/4885PIM1 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.